Benzinga | Apr 6, 2021 07:33AM EDT

Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings

* The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China.

* The trial will evaluate the safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).

* ATG-019 is a dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc (NASDAQ: KPTI).

* Antengene reached an exclusive agreement with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in Greater China, South Korea, Australia, New Zealand, and ASEAN countries.

* Antengene is conducting a Phase 1 trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and is planning to conduct clinical trials exploring its combination potential with other agents.

* Price Action: KPTI shares are up 4.95% at $11.66 in the premarket session on the last check Tuesday.